Replies to post #127162 on Biotech Values

[pcrutch]

Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: $MNTA) price target of $15.00.

Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on generic Copaxone potential, biosimilars. We think m-enox sales revenue to MNTA will decline rapidly from Q4/11 on Amphastar’s enox launch. We still think that the recently completed Teva generic Copaxone infringement trial will result in MNTA/Sandoz’s favor (we think mid-2012) and that MNTA will become a biosimilars development leader."

======

$MNTA Rodman & Renshaw notes ($TEVA $NVS lovenox, copaxone, $ plans, confirms multiple FOBs- only disclose w/ partner) - www.goo.gl/KQkp1

======

UBS upgrades to buy based on valuation. 50 % upside from here.